Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VMSSD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ASG-5ME
|
|||||
| Synonyms |
ASG 5 ME; ASG-5-ME; ASG 5ME
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.; Agensys, Inc.; Astellas Pharma, Inc.
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 3 Indication(s)
Gastric cancer [ICD11:2B72]
Terminated in phase 1
Pancreatic cancer [ICD11:2C10]
Terminated in phase 1
Prostate cancer [ICD11:2C82]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.7
|
|||||
| Structure |
|
|||||
| Antibody Name |
Human IgG2 Anti-SLC44A4 mAb
|
Antibody Info | ||||
| Antigen Name |
Choline transporter-like protein 4 (SLC44A4)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
| DrugMap ID | ||||||
| TTD ID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.